Palani Palaniappan, Ph.D.

Vice President & Head, Biologics & New Modalities Development, Takeda Pharmaceuticals

Dr. Palani is currently head of global biologics CMC at Takeda. Throughout his tenure at Takeda and previously at BiogenIdec, Gilead Sciences and Par Pharmaceuticals, he has been interested in integral approaches of drug development. He has participated in CMC development and manufacturing of a number of marketed products to help patients with debilitating diseases. Dr. Palani obtained his BS/MA from Annamalai University and PhD from IIT-Kanpur. He had also spent several years as a post-doc at Virginia Commonwealth University, Richmond, VA and University of California, Riverside, CA.